Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, US.
Recent Results Cancer Res. 2021;217:197-207. doi: 10.1007/978-3-030-57362-1_9.
Epstein-Barr virus (EBV) is associated with a variety of malignancies including post-transplant lymphoproliferative disease (PTLD). These include B and T cell lymphomas, epithelial, and mesenchymal tumors. The virus is ubiquitous, transmitted in saliva, and not usually associated with the development of malignancy. PTLD is usually associated with EBV when it occurs soon after the transplant. Measurement of viral DNA in blood, especially plasma, may be useful in the diagnosis of PTLD. Treatment approaches include withdrawal of immunosuppression, monoclonal antibodies or antibody conjugates, cytotoxic chemotherapy, and a variety of virus-specific treatments such as adoptive cellular therapy with EBV-specific T cells. Approaches to prevention include selection of immunosuppressive regimens that minimize the risk. In the future, EBV vaccines may be available for potential transplant recipients.
EB 病毒（EBV）与多种恶性肿瘤相关，包括移植后淋巴组织增生性疾病（PTLD）。这些肿瘤包括 B 细胞和 T 细胞淋巴瘤、上皮和间叶肿瘤。该病毒普遍存在，通过唾液传播，通常不会导致恶性肿瘤的发生。PTLD 通常与移植后不久发生的 EBV 相关。血液中病毒 DNA 的测量，特别是血浆中的 EBV DNA 测量，对 PTLD 的诊断可能有用。治疗方法包括免疫抑制药物的撤药、单克隆抗体或抗体偶联物、细胞毒性化疗以及各种病毒特异性治疗，如 EBV 特异性 T 细胞过继细胞治疗。预防方法包括选择可将风险降至最低的免疫抑制方案。将来，可能会有针对潜在移植受者的 EBV 疫苗。
